The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results were announced in a news release and have not yet been peer-reviewed., last year. Biogen partnered with Eisai in the commercialization of the new drug, although Eisai led its development and the phase 3 trial.The results are “a first step in the direction of making a significant impact on the disease,” said Dr.
Dr. Alberto Espay, a neurologist at the University of Cincinnati College of Medicine, said that the benefit was "small" and that it fell below the threshold of what would be meaningful to a patient. Still, he said, "patients can view this with cautious optimism." The results were based on 1,795 patients, who were randomly assigned to receive either the drug or a placebo every two weeks over 18 months. Cognitive decline was measured using a clinical dementia rating scale that focused on six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.
Eisai said that it will present the findings at an Alzheimer’s conference in late November and that it plans to submit the trial data to the Food and Drug Administration for approval by March. Eisai's drug is a monoclonal antibody designed to target amyloid plaques, clumps of protein in the brain long considered a hallmark of Alzheimer’s.
Avoiding mRNA vaccine is the best.
I think I seen something stating viagra an other similar drugs improve blood flow to brain in Alzheimer’s